Here's my thought. When they're running the study, there's a good chance they'll use cogstate battery as established technique to compare against. IF the study is proven to be successful, it'll probably have impact on loyalties that Cogstate receives from healthcare segment? On the other hand, Eli Lily's published successful phase 2 clinical study result of their alzheimer's disease drug, donanemab. I know it'll be years from phase 3 but any successful alzheimer's drug will benefit cogstate.
Biogen and Apple study early signs of Cognitive Impairment, page-2
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.015(1.60%) |
Mkt cap ! $157.9M | |||
| Open | High | Low | Value | Volume |
| 92.5¢ | 95.0¢ | 91.5¢ | $157.5K | 170.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3377 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.5¢ | 246 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |